Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 198

Science

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19